Jump to content

Carotuximab

From Wikipedia, the free encyclopedia
Carotuximab
Monoclonal antibody
Type?
SourceChimeric (mouse/human)
Targetendoglin
Clinical data
Other namesTRC-105
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6420H9922N1718O2010S46
Molar mass144808.77 g·mol−1

Carotuximab (INN[1]) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.

This drug was developed by Tracon Pharmaceuticals Inc.[2]

It is at Phase III trials for angiosarcoma.

References

[edit]
  1. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Carotuximab, American Medical Association.